Patents by Inventor Michel Dib

Michel Dib has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Application of 2-cyano-10- (2-methyl-3- (methylamino)- propyl) phenothiazine or a pharmaceutically acceptable salt as medicament
    Patent number: 7538106
    Abstract: The present invention relates to the application of 2-cyano-10-(2-methyl-3-(methylamino)-propyl)phenothiazine or a pharmaceutically acceptable salt thereof to produce a medicament intended for the treatment of sleep disorders, anxiety disorders, mood disorders, mixed anxiety-depression disorder, acute and chronic psychotic state, addiction to and withdrawal from a substance, extrapyramidal events induced by antipsychotics, or symptomatic dimensions during acute or chronic psychotic states as monotherapy or in combination with other antipsychotics.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: May 26, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michel Dib, Ahcene Hameg
  • Combination of cyamemazine and an atypical neuroleptic
    Patent number: 6982262
    Abstract: The present invention relates to the combination of cyamemazine and an atypical neuroleptic, or a pharmaceutically acceptable salt thereof, and to the use thereof in the treatment of schizophrenia, and in particular of acute episodes of schizophrenia.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: January 3, 2006
    Assignee: Aventis Pharma S. A.
    Inventors: Michel Dib, Cyrille Leperlier
  • Application of 2-cyano-10- (2-methyl-3- (methylamino)- propyl) phenothiazine or a pharmaceutically acceptable salt as medicament
    Publication number: 20040171610
    Abstract: The present invention relates to the application of 2-cyano-10-(2-methyl-3-(methylamino)-propyl)phenothiazine or a pharmaceutically acceptable salt thereof to produce a medicament intended for the treatment of sleep disorders, anxiety disorders, mood disorders, mixed anxiety-depression disorder, acute and chronic psychotic state, addiction to and withdrawal from a substance, extrapyramidal events induced by antipsychotics, or symptomatic dimensions during acute or chronic psychotic states as monotherapy or in combination with other antipsychotics.
    Type: Application
    Filed: February 6, 2004
    Publication date: September 2, 2004
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Michel Dib, Ahcene Hameg
  • Combination of cyamemazine and an atypical neuroleptic
    Publication number: 20040167125
    Abstract: The present invention relates to the combination of cyamemazine and an atypical neuroleptic, or a pharmaceutically acceptable salt thereof, and to the use thereof in the treatment of schizophrenia, and in particular of acute episodes of schizophrenia.
    Type: Application
    Filed: February 20, 2004
    Publication date: August 26, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Michel Dib, Cyrille Leperlier
  • Combination of cyamemazine and an atypical neuroleptic
    Patent number: 6720318
    Abstract: The present invention relates to the combination of cyamemazine and an atypical neuroleptic, olanzapine or risperidone, or a pharmaceutically acceptable salt thereof, and to the use thereof in the treatment of schizophrenia, and in particular, of acute episodes of schizophrenia.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: April 13, 2004
    Assignee: Aventis Pharma S. A.
    Inventors: Michel Dib, Cyrille Leperlier
  • Use of nicergoline in the treatment of spasticity
    Patent number: 6713493
    Abstract: The invention concerns the use of nicergoline for treating pyramidal spasticity of neurological diseases involving a pathology of the cerebrospinal tract.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: March 30, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Dib, Vincent Meininger
  • Riluzole and alpha-tocopherol combination
    Patent number: 6642262
    Abstract: The invention concerns a combination of alpha-tocopherol and riluzole or a pharmaceutically acceptable salt thereof and the use of said combination for treating amyotrophic lateral sclerosis.
    Type: Grant
    Filed: May 11, 2001
    Date of Patent: November 4, 2003
    Assignee: Aventia Pharma S.A.
    Inventor: Michel Dib
  • Novel therapeutic use of nicergoline
    Publication number: 20030134869
    Abstract: The invention concerns the use of nicergoline for preventing and/or treating motor neuron diseases.
    Type: Application
    Filed: August 14, 2002
    Publication date: July 17, 2003
    Inventor: Michel Dib
  • Riluzole and alpha-tocopherol combination
    Publication number: 20030125363
    Abstract: The invention concerns a combination of alpha-tocopherol and riluzole or a pharmaceutically acceptable salt thereof and the use of said combination for treating amyotrophic lateral sclerosis.
    Type: Application
    Filed: February 18, 2003
    Publication date: July 3, 2003
    Inventor: Michel Dib
  • Combination of cyamemazine and an atypical neuroleptic
    Publication number: 20020183312
    Abstract: The present invention relates to the combination of cyamemazine and an atypical neuroleptic, or a pharmaceutically acceptable salt thereof, and to the use thereof in the treatment of schizophrenia, and in particular of acute episodes of schizophrenia.
    Type: Application
    Filed: June 7, 2002
    Publication date: December 5, 2002
    Inventors: Michel Dib, Cyrille Leperlier
  • Therapeutic application of nicergoline
    Patent number: 6469019
    Abstract: The invention concerns the use of nicergoline for preventing and/or treating motor neuron diseases.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: October 22, 2002
    Assignee: Aventis Pharma S.A.
    Inventor: Michel Dib
  • Therapeutic use of 1,6-dimethyl-8&bgr;-hydroxymethyl-10&agr;-methoxyergoline
    Patent number: 6451818
    Abstract: The invention concerns the use of 1,6-dimethyl-8&bgr;-hydroxymethyl-10&agr;-methoxyergoline for preventing and/or treating motor neuron diseases.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: September 17, 2002
    Assignee: Aventis Pharma S.A.
    Inventor: Michel Dib
  • Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
    Patent number: 6432992
    Abstract: The present invention relates to the use of riluzole or one of its pharmaceutically acceptable salts for the prevention and treatment of adrenoleukodystrophy.
    Type: Grant
    Filed: June 5, 2001
    Date of Patent: August 13, 2002
    Assignees: Aventis Pharm SA, Institut Nationale de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Patrick Aubourg, Michel Dib, Jean-Marie Stutzmann
  • Use of nicergoline in the treatment of spasticity
    Publication number: 20020086875
    Abstract: The invention concerns the use of nicergoline for treating pyramidal spasticity of neurological diseases involving a pathology of the cerebrospinal tract.
    Type: Application
    Filed: January 29, 2002
    Publication date: July 4, 2002
    Inventors: Michel Dib, Vincent Meininger
  • Novel therapeutic use of 1,6-dimethyl-8b-hydroxymethyl-10a-methoxyergoline
    Publication number: 20020065294
    Abstract: The invention concerns the use of 1,6-dimethyl-8&bgr;-hydroxymethyl-10&agr;-methoxyergoline for preventing and/or treating motor neuron diseases.
    Type: Application
    Filed: November 29, 2001
    Publication date: May 30, 2002
    Inventor: Michel Dib
  • Use of nicergoline for treating spasticity
    Patent number: 6380208
    Abstract: The invention concerns the use of nicergoline for treating pyramidal spasticity of neurological diseases involving a pathology of the cerebrospinal tract.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: April 30, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Dib, Vincent Meininger
  • Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
    Publication number: 20020037902
    Abstract: The present invention relates to the use of riluzole or one of its pharmaceutically acceptable salts for the prevention and treatment of adrenoleukodystrophy.
    Type: Application
    Filed: June 5, 2001
    Publication date: March 28, 2002
    Inventors: Patrick Aubourg, Michel Dib, Jean-Marie Stutzmann
  • Riluzole and alpha-tocopherol combination
    Publication number: 20020019426
    Abstract: The invention concerns a combination of alpha-tocopherol and riluzole or a pharmaceutically acceptable salt thereof and the use of said combination for treating amyotrophic lateral sclerosis.
    Type: Application
    Filed: May 11, 2001
    Publication date: February 14, 2002
    Inventor: Michel Dib
  • Use of nicergoline for treating spasticity
    Publication number: 20020013332
    Abstract: The invention concerns the use of nicergoline for treating pyramidal spasticity of neurological diseases involving a pathology of the cerebrospinal tract.
    Type: Application
    Filed: May 23, 2001
    Publication date: January 31, 2002
    Inventors: Michel Dib, Vincent Meininger
  • Therapeutic use of 1, 6-dimethyl-8&bgr;-hydroxymethyl-10-&agr;-methoxyergoline
    Patent number: 6339095
    Abstract: The invention concerns the use of 1,6-dimethyl-8&bgr;-hydroxymethyl-10&agr;-methoxyergoline for preventing and/or treating motor neuron diseases.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: January 15, 2002
    Assignee: Aventis Pharma S.A.
    Inventor: Michel Dib